150 related articles for article (PubMed ID: 12414529)
21. A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides.
van Kester MS; Borg MK; Zoutman WH; Out-Luiting JJ; Jansen PM; Dreef EJ; Vermeer MH; van Doorn R; Willemze R; Tensen CP
J Invest Dermatol; 2012 Aug; 132(8):2050-9. PubMed ID: 22513784
[TBL] [Abstract][Full Text] [Related]
22. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
23. The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.
Lesinski GB; Anghelina M; Zimmerer J; Bakalakos T; Badgwell B; Parihar R; Hu Y; Becknell B; Abood G; Chaudhury AR; Magro C; Durbin J; Carson WE
J Clin Invest; 2003 Jul; 112(2):170-80. PubMed ID: 12865406
[TBL] [Abstract][Full Text] [Related]
24. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
[TBL] [Abstract][Full Text] [Related]
25. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.
Fantin VR; Loboda A; Paweletz CP; Hendrickson RC; Pierce JW; Roth JA; Li L; Gooden F; Korenchuk S; Hou XS; Harrington EA; Randolph S; Reilly JF; Ware CM; Kadin ME; Frankel SR; Richon VM
Cancer Res; 2008 May; 68(10):3785-94. PubMed ID: 18483262
[TBL] [Abstract][Full Text] [Related]
26. STAT5 contributes to interferon resistance of melanoma cells.
Wellbrock C; Weisser C; Hassel JC; Fischer P; Becker J; Vetter CS; Behrmann I; Kortylewski M; Heinrich PC; Schartl M
Curr Biol; 2005 Sep; 15(18):1629-39. PubMed ID: 16169484
[TBL] [Abstract][Full Text] [Related]
27. Treatment of childhood cutaneous T-cell lymphoma with alpha-interferon plus PUVA.
Tay YK; Weston WL; Aeling JL
Pediatr Dermatol; 1996; 13(6):496-500. PubMed ID: 8987062
[TBL] [Abstract][Full Text] [Related]
28. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).
Gu Z; Lee RY; Skaar TC; Bouker KB; Welch JN; Lu J; Liu A; Zhu Y; Davis N; Leonessa F; Brünner N; Wang Y; Clarke R
Cancer Res; 2002 Jun; 62(12):3428-37. PubMed ID: 12067985
[TBL] [Abstract][Full Text] [Related]
29. High density oligonucleotide array analysis of interferon- alpha2a sensitivity and transcriptional response in melanoma cells.
Certa U; Seiler M; Padovan E; Spagnoli GC
Br J Cancer; 2001 Jul; 85(1):107-14. PubMed ID: 11437411
[TBL] [Abstract][Full Text] [Related]
30. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
Lesinski GB; Kondadasula SV; Crespin T; Shen L; Kendra K; Walker M; Carson WE
J Natl Cancer Inst; 2004 Sep; 96(17):1331-42. PubMed ID: 15339971
[TBL] [Abstract][Full Text] [Related]
31. Versican upregulation in Sézary cells alters growth, motility and resistance to chemotherapy.
Fujii K; Karpova MB; Asagoe K; Georgiev O; Dummer R; Urosevic-Maiwald M
Leukemia; 2015 Oct; 29(10):2024-32. PubMed ID: 25915825
[TBL] [Abstract][Full Text] [Related]
32. Differential responses to IFN-alpha subtypes in human T cells and dendritic cells.
Hilkens CM; Schlaak JF; Kerr IM
J Immunol; 2003 Nov; 171(10):5255-63. PubMed ID: 14607926
[TBL] [Abstract][Full Text] [Related]
33. Interferon alpha induction of Stat1 and Stat2 and their prognostic significance in carcinoid tumors.
Zhou Y; Wang S; Gobl A; Oberg K
Oncology; 2001; 60(4):330-8. PubMed ID: 11408801
[TBL] [Abstract][Full Text] [Related]
34. Functional annotation of IFN-alpha-stimulated gene expression profiles from sensitive and resistant renal cell carcinoma cell lines.
Holko M; Williams BR
J Interferon Cytokine Res; 2006 Aug; 26(8):534-47. PubMed ID: 16881864
[TBL] [Abstract][Full Text] [Related]
35. Coexpression of CD40 and CD40 ligand in cutaneous T-cell lymphoma (mycosis fungoides).
Storz M; Zepter K; Kamarashev J; Dummer R; Burg G; Häffner AC
Cancer Res; 2001 Jan; 61(2):452-4. PubMed ID: 11212229
[TBL] [Abstract][Full Text] [Related]
36. Sodium butyrate enhances STAT 1 expression in PLC/PRF/5 hepatoma cells and augments their responsiveness to interferon-alpha.
Hung WC; Chuang LY
Br J Cancer; 1999 May; 80(5-6):705-10. PubMed ID: 10360647
[TBL] [Abstract][Full Text] [Related]
37. Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals.
Kortylewski M; Komyod W; Kauffmann ME; Bosserhoff A; Heinrich PC; Behrmann I
J Invest Dermatol; 2004 Feb; 122(2):414-22. PubMed ID: 15009724
[TBL] [Abstract][Full Text] [Related]
38. Alternating recombinant and natural alpha-interferon helps to prevent clinical resistance to interferon in cutaneous T-cell lymphoma treatment.
Altomare G; Capella GL; Frigerio E
Acta Derm Venereol; 1998 Mar; 78(2):159. PubMed ID: 9534907
[No Abstract] [Full Text] [Related]
39. Adhesion, migration, transcriptional, interferon-inducible, and other signaling molecules newly implicated in cancer susceptibility and resistance of JB6 cells by cDNA microarray analyses.
Samuel S; Bernstein LR
Mol Carcinog; 2004 Jan; 39(1):34-60. PubMed ID: 14694446
[TBL] [Abstract][Full Text] [Related]
40. Expression of the JAK and STAT superfamilies in human meningiomas.
Magrassi L; De-Fraja C; Conti L; Butti G; Infuso L; Govoni S; Cattaneo E
J Neurosurg; 1999 Sep; 91(3):440-6. PubMed ID: 10470819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
